DC Week: ACA Defunding Fight Continues MedPage Today Boxed Warning of HBV Risk Added to Rituxan, Arezerra. The FDA announced Friday that rituximab (Rituxan) and ofatumumab (Arzerra) will now carry a boxed warning stating the risk for immunosuppression-related reactivation of hepatitis B virus (HBV). |
